Biggest News Aggregation in the World
📰 Randomized Controlled Study News

Randomized Controlled Study News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Randomized Controlled Study. Real-time updates on events, politics, business and more.

ZUMA-23: A Global, Phase 3, Randomized Controlled Study of Axicabtagene Ciloleucel Versus Standard-of-Care as First-Line Therapy in Patients With High-Risk Large B-Cell Lymphoma

Jason R. Westin, MD, MS, FACP, reviews the background and study design of ZUMA-23, the first Phase III, randomized controlled study to evaluate CAR T-cell therapy as a first-line regimen in patients with high-risk LBCL.
Jasonr Westin Randomized Controlled Study Axicabtagene Ciloleucel Versus Standard Of Care First Line Therapy Patients With High Risk Largeb Cell Zuma 23

Gilead Sciences, Inc.: Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA

- Eight Presentations on Yescarta and TecartusAdvance Kite's Cell Therapy Leadership - - New Data Highlight Magrolimab's Potential to Alter the Tumor Microenvironment - Gilead Sciences, Inc. (Nasdaq:
United States Foster City Carol Ohear Frank Neumann Jacquie Ross Brexucabtagene Autoleucel

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023

– Data Across 30 Abstracts Reinforce Leadership in Metastatic Breast Cancer and Demonstrate Breadth of Pipeline Across Lung, Hematologic, Genitourinary, Gastrointestinal, Gynecological and... | May 17, 2023
Foster City United States Domvanalimab Dom Pembrolizumab Pembro Etrumadenant Etruma Axicabtagene Ciloleucel

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science